The United States Patent and Trademark Office awards Nuwellis a patent for
MINNEAPOLIS, Aug. 25, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial company dedicated to transforming the lives of patients suffering from fluid overload, today announced that it has been granted a state patent United Patent and Trademark Office for a new innovation that improves fluid balance and safety in pediatric dialysis and hemofiltration.
“We continue to invest in technology advancements that have meaningful impact for patients and clinicians,” said Nestor Jaramillo, Jr., President and CEO of Nuwellis. “Clinicians rely on us to provide cutting-edge technology that gives them the flexibility to easily and safely expand treatment options for their young patients. We are pleased to have received a patent for this groundbreaking innovation that can enhance current and future technology development initiatives. »
The new innovations included in this patent will allow healthcare providers to detect pressure changes in the operation of externally connected pumps so that clinicians can make necessary therapeutic modifications.
Nuwellis is currently developing a novel, fully integrated Continuous Renal Replacement Therapy (CRRT) pediatric device designed to provide care for small babies and children. This device is funded in part by a $1.7 million grant from the National Institutes of Health (NIH). The company has partnered with Minneapolis-based research and development company Koronis Biomedical Technologies Corporation (KBT), the grant recipient, to design and develop a personalized pediatric product that will enable clinicians to better care babies with limited kidney function.
Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients with fluid overload through science, collaboration and innovation. The Company is focused on developing, manufacturing and marketing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow System provides clinically proven therapy using a simple, flexible and predictable method to remove excess fluid in patients with hypervolemia (fluid overload). The Aquadex SmartFlow System is indicated for temporary (up to 8 hours) or prolonged (greater than 8 hours in patients requiring hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload does not respond to medical management, including diuretics. All treatments should be administered by a healthcare provider, in an outpatient or inpatient clinical setting, under medical prescription, both of whom have received training in extracorporeal therapies.
Certain statements in this release may be deemed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding new market opportunities and expected growth in 2022 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, therefore, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements contained in this release, including, without limitation, risks associated with our ability to execute our go-to-market strategy, the impact of the pandemic of COVID-19, the possibility that we may be unable to raise sufficient funds necessary for our planned operations, our post-marketing clinical data collection activities, the benefits of our products to patients, our expectations for the development of products and marketing efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, protection of intellectual property, our ability to integrate acquired businesses, our expectations regarding anticipated synergies and benefits of acquired businesses, and other risks and t uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date they are made. Nuwellis undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.